Copy Number of Cancer Gene Mutations Adds Prognostic and Organ-Specific Metastasis Prediction Information
Background
In cancer genomic analysis, the focus is typically on identifying the presence of specific somatic mutations. However, the gene mutation dosage (GMD), which represents the number of gene copies with the mutation, may also be relevant to tumor evolution. Calculating GMD requires the joint interpretation of somatic mutations and copy number alterations. The researchers developed INCOMMON, a Bayesian tool that estimates mutation copy number and multiplicity from targeted sequencing data without requiring normal control samples, and applied it to large-scale clinical datasets of various cancer types. This method probabilistically estimates tumor purity and read counts per chromosome copy to calculate the gene state created by the combined effects of mutations and copy number alterations.
Key Findings
The researchers analyzed over 60,000 clinical cancer samples and over 500,000 mutations obtained from 39 major solid tumor types. In cross-validation, the proportion of predictions with a total copy number and mutation multiplicity error of less than one copy was 78.6% and 96.4%, respectively. Dividing over 20,000 patients into groups based on the GMD of multiple genes revealed 46 cancer-specific biomarkers that predicted overall survival. Among these, 13 were not identified by conventional methods that only distinguish the presence or absence of mutations. Additionally, 26 biomarkers were associated with metastatic spread, and 20 predicted the tendency to metastasize to specific organs. These results demonstrate statistical associations and predictive performance, but do not prove a causal relationship where GMD directly causes metastasis.
Significance and Prospects
INCOMMON is designed to estimate mutation copy number and multiplicity from read counts in clinical targeted sequencing without requiring raw FASTQ or BAM files or normal control samples. Adding GMD information to the presence or absence of mutations can broaden the scope of identifying prognostic and metastasis-related biomarkers. The ability to re-analyze previously accumulated clinical panel data also enhances the research's applicability. However, to use the analysis results in actual treatment decisions, reproducibility should be confirmed in an independent patient cohort, and clinical utility should be prospectively validated for each cancer type and treatment method. The current findings do not represent the immediate completion of precision medicine, but rather present a computational method that refines biomarker discovery.
Nature Genetics, Published online: 31 July 2026; doi:10.1038/s41588-026-02666-zThe authors present INCOMMON, an open-source Bayesian inference tool that determines the multiplicity and copy number of driver mutations from tumor sequencing datasets.
Even tumors with the same driver mutation can have different clinical outcomes depending on the copy number of the mutation and the surrounding copy number alterations. The researchers showed that GMD can be independently associated with survival, metastatic potential, and organ-specific metastasis in over 60,000 samples. Importantly, they identified additional biomarkers that were missed by simple mutation presence/absence analysis. However, these are predictive results obtained from retrospective large-scale data, so external validation and prospective evaluation are needed before applying them to patient treatment.